pfizer – pharma.markets

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months

01/04/2021 MaP 0

…Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective […]

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

25/02/2021 MaP 0

The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that […]

In Vitro Study Published in The New England Journal of Medicine

17/02/2021 MaP 0

Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations Pfizer Inc. (NYSE: PFE) and BioNTech SE […]

Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

17/02/2021 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses […]

Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine

12/02/2021 MaP 0

U.S. government exercises option to bring total supply to 300 million doses, enabling vaccinations for 150 million people Pfizer Inc. (NYSE: PFE) and BioNTech SE […]

Pfizer and BioNTech Publish Data from In Vitro Studies

08/02/2021 MaP 0

….in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants Pfizer Inc. (NYSE: PFE) […]

Pfizer and BioNTech Publish Results of Study

20/01/2021 MaP 0

Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture Today, Pfizer Inc. (NYSE: PFE) and BioNTech […]

Statement regarding European Commission’s Proposal to Purchase Additional Doses of BioNTech-Pfizer Vaccine

08/01/2021 MaP 0

We are in talks with the European Commission (EC) about an amendment to our existing supply agreement for COMIRNATY®, the Pfizer-BioNTech COVID-19 Vaccine. The amendment […]

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation

08/01/2021 MaP 0

Associated with Rapid Transmission Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and […]

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®

29/12/2020 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, […]

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine COMIRNATY

21/12/2020 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer […]

Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2

14/12/2020 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial […]